• Blood Cancers
  • Genitourinary Cancers
  • Brain Cancer
  • Breast Cancer
  • Childhood Cancers
  • Gastric Cancers
  • Gynecologic Cancer
  • Head & Neck Cancer
  • Immunotherapy
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Myeloma
  • Rare Cancers
  • Sarcoma
  • Skin Cancer
  • Thyroid Cancer

Imfinzi in Combination with Standard-of-Care Chemotherapies Improves Survival in Lung Cancer


Final results of the phase 3 CASPIAN trial show that Imfinzi (durvalumab) in combination with a choice of standard-of-care chemotherapies demonstrates a sustained overall survival benefit in patients with extensive-stage small cell lung cancer.

Imfinzi (durvalumab), in combination with a select few standard-of-care chemotherapies, showed a sustained and clinically meaningful overall survival benefit in patients with extensive-stage small cell lung cancer, according to final analysis of the phase 3 CASPIAN trial.

“We are pleased to see the sustained and meaningful survival benefit of Imfinzi for patients with small cell lung cancer after more than two years median follow up,” Jose Baselga, executive vice president of oncology research and development at AstraZeneca, said in a company-issued press release. “We have already received the first global regulatory approval for Imfinzi with etoposide plus either carboplatin or cisplatin and remain on track for more approvals soon as we provide patients an important new first-line treatment option.”

Imfinzi — a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80 — counters the tumor's immune-evading tactics and releases the inhibition of immune responses.

Previous results of the trial showed that Imfinzi plus etoposide and either carboplatin or cisplatin chemotherapy improved overall survival — defined by the start of treatment until the time of patient death — versus standard-of-care chemotherapy alone.

Safety and tolerability data for Imfinzi were similar to previous safety results and will be presented at a future medical conference.

Related Videos
Image of a woman with dark brown hair and round glasses wearing pearl earrings.
A man with a dark gray button-up shirt with glasses and cropped brown hair.
Woman with dark brown hair and pink lipstick wearing a light pink blouse with a light brown blazer. Patients should have conversations with their providers about treatments after receiving diagnoses.
Man in a navy suit with a purple tie. Dr. Saby George talks to CURE about how treatment with Opdivo could mitigate disparities in patients with kidney cancer.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE